MX2021008928A - Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química. - Google Patents
Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.Info
- Publication number
- MX2021008928A MX2021008928A MX2021008928A MX2021008928A MX2021008928A MX 2021008928 A MX2021008928 A MX 2021008928A MX 2021008928 A MX2021008928 A MX 2021008928A MX 2021008928 A MX2021008928 A MX 2021008928A MX 2021008928 A MX2021008928 A MX 2021008928A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- survival
- vascular injury
- response
- protection against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796728P | 2019-01-25 | 2019-01-25 | |
| PCT/US2020/015015 WO2020154637A1 (en) | 2019-01-25 | 2020-01-24 | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008928A true MX2021008928A (es) | 2021-11-04 |
Family
ID=69740564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008928A MX2021008928A (es) | 2019-01-25 | 2020-01-24 | Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237872A1 (enExample) |
| EP (1) | EP3914281A1 (enExample) |
| JP (1) | JP7664163B2 (enExample) |
| KR (1) | KR20210119469A (enExample) |
| CN (1) | CN113660943A (enExample) |
| AU (1) | AU2020210869A1 (enExample) |
| CA (1) | CA3127458A1 (enExample) |
| IL (1) | IL285092A (enExample) |
| MA (1) | MA54821A (enExample) |
| MX (1) | MX2021008928A (enExample) |
| WO (1) | WO2020154637A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7481252B2 (ja) | 2017-07-26 | 2024-05-10 | ヤンセン ファーマシューティカ エヌ．ベー． | 標的放射線治療誘発性血管完全性を保護する方法 |
| MA54820A (fr) * | 2019-01-25 | 2021-12-01 | Janssen Pharmaceutica Nv | Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques |
| CN118660955A (zh) * | 2021-10-01 | 2024-09-17 | 詹森药业有限公司 | 增加祖细胞生产的方法 |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680422B2 (en) | 1992-06-11 | 1997-07-31 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| RS20060141A (sr) | 2003-08-28 | 2008-08-07 | Ortho-Mcneil Pharmaceutical Inc., | Peptidi i jedinjenja koja se vežu za receptor |
| US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| US20060210542A1 (en) | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| PT1984014E (pt) | 2006-02-14 | 2014-11-13 | Janssen Pharmaceutica Nv | Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia |
| KR20110015448A (ko) | 2008-06-03 | 2011-02-15 | 얀센 파마슈티카 엔.브이. | 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드 |
| BR112014028094B1 (pt) * | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| US20140051631A1 (en) * | 2012-08-17 | 2014-02-20 | Francoise Porteu | Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| JP6150374B2 (ja) * | 2012-11-15 | 2017-06-21 | 国立大学法人弘前大学 | 放射線被ばく治療剤及び放射線被ばく治療方法 |
-
2020
- 2020-01-24 US US16/752,559 patent/US20200237872A1/en not_active Abandoned
- 2020-01-24 CA CA3127458A patent/CA3127458A1/en active Pending
- 2020-01-24 WO PCT/US2020/015015 patent/WO2020154637A1/en not_active Ceased
- 2020-01-24 AU AU2020210869A patent/AU2020210869A1/en not_active Abandoned
- 2020-01-24 JP JP2021542516A patent/JP7664163B2/ja active Active
- 2020-01-24 EP EP20708763.6A patent/EP3914281A1/en not_active Withdrawn
- 2020-01-24 MX MX2021008928A patent/MX2021008928A/es unknown
- 2020-01-24 MA MA054821A patent/MA54821A/fr unknown
- 2020-01-24 KR KR1020217026699A patent/KR20210119469A/ko not_active Ceased
- 2020-01-24 CN CN202080023563.6A patent/CN113660943A/zh active Pending
-
2021
- 2021-07-23 IL IL285092A patent/IL285092A/en unknown
-
2022
- 2022-02-18 US US17/651,675 patent/US20220168392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220168392A1 (en) | 2022-06-02 |
| US20200237872A1 (en) | 2020-07-30 |
| KR20210119469A (ko) | 2021-10-05 |
| JP7664163B2 (ja) | 2025-04-17 |
| JP2022519196A (ja) | 2022-03-22 |
| IL285092A (en) | 2021-09-30 |
| WO2020154637A9 (en) | 2020-08-27 |
| WO2020154637A1 (en) | 2020-07-30 |
| CA3127458A1 (en) | 2020-07-30 |
| EP3914281A1 (en) | 2021-12-01 |
| AU2020210869A1 (en) | 2021-08-19 |
| CN113660943A (zh) | 2021-11-16 |
| MA54821A (fr) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| MX2015003643A (es) | Metodo para tratar el cancer. | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
| AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| MX2020011727A (es) | Terapia adjuntiva con 25-hidroxi vitamina d y artículos de los mismos. | |
| AR125921A1 (es) | Terapia de combinación | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| CL2019001304A1 (es) | Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2021008943A (es) | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| MX2020001727A (es) | Terapia de combinacion. | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| PH12020500166A1 (en) | Method of protecting vascular integrity induced by targeted radiation therapy | |
| IL285092A (en) | Methods to increase protection against injury to organs and blood vessels, hematopoietic recovery and survival in response to radiation/chemical exposure throughout the body | |
| DOP2022000109A (es) | MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYU-VANTE ARTIFICIAL (aAVC) | |
| UY33790A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek. | |
| EA202192964A1 (ru) | Комбинированная терапия |